June 19-22, 2017 | San Diego, CA

Double Helix Sponsor


Schedule at a glance

Registration Rates

Join the Mailing List



BIO Buzz - Official Show Daily, Brought to you by Alexandria

Health Care


#BIO2016: June 6-9, 2016 in San Francisco
Habib Dable, Bayer at the 2016 BIO International Convention
Laurance Stuntz, Massachusetts eHealth Institute at the 2016 BIO International Convention
Geoffrey Eich, Amgen at the 2016 BIO International Convention
Dr. Jake Reder, Celdara Medical at the 2016 BIO International Convention
Dr. Asha Das, Tocagen at the 2016 BIO International Convention
Lee Jones, Rebiotix at the 2016 BIO International Convention

Articles from BioTechNow

Alzheimer’s Research: Where We’ve Failed and What’s To Come

Publish Date: 11/28/2016, Created By: BIOtechNOW Editor

Alzheimer’s disease is a rapidly growing public health crisis. Today an estimated 5.4 million Americans live with the disease and, barring the development of medical breakthroughs to prevent, stop or slow Alzheimer’s disease by 2050, the number of people age 65 and older with Alzheimer’s disease may reach as high as 16 million people. What’s more, at a cost of $236 billion a year, Alzheimer’s is the most expensive disease in the nation with an ...

Read More >

Lawsuit Against UnitedHealth Put Insurers’ Practices Under Scrutiny

Publish Date: 10/12/2016, Created By: Jim Greenwood

Reuters reports that UnitedHealth Group, the nation’s largest insurer, has been sued by three patients who’ve accused the massive insurance conglomerate of significantly over-charging them for co-pays for prescription drugs. The report alleges the co-pays were far in excess of the actual cost of the drug and the insurer kept the difference. According to Reuters: “For example, the lawsuit claims, one class member paid a $50 co-payment for Sprintec, a contraceptive, while UnitedHealth paid the ...

Read More >

NORD President: Congress must act now to help 15 million sick children

Publish Date: 9/19/2016, Created By: Daniel Seaton

Writing in The Hill, National Organization for Rare Disorders (NORD) President and CEO Peter Saltonstall called upon Congress to act swiftly to maintain an important program encouraging research into treatments for rare pediatric diseases. The Rare Pediatric Priority Review Voucher (PRV) Program is set to expire at the end of the month, unless Congress reauthorizes it. Saltonstall writes: Developing therapies for people with rare diseases is incredibly difficult. Rare diseases are scientifically and medically complex, ...

Read More >

Challenging Entrepreneurs to Heal the World

Publish Date: 8/23/2016, Created By: BIOtechNOW Editor

The healthcare industry needs a refresh! Through improvements in medicine, sanitation and general living conditions, we’ve made great strides at fighting many of the maladies that have plagued humanity for centuries, lowering child mortality rates while increasing life spans by decades. Yet as a consequence of living longer, we’re facing new health issues and the increasing prevalence of chronic conditions and , neurodegenerative,  metabolic and immunological diseases. Despite scientific advancements in many fields, insufficient progress ...

Read More >

The Washington Post Unfairly Attacks The Orphan Drug Act

Publish Date: 8/8/2016, Created By: Jim Greenwood

The Orphan Drug Act has been a tremendous success and addressed a market failure by providing incentives to bring new treatments to those suffering with rare diseases. That’s why I was deeply troubled by Friday’s unfair article in The Washington Post targeting the Orphan Drug Act through selective and unsubstantiated attacks that seem designed to undermine this bipartisan and hugely successful regime that has helped so many patients with rare diseases live longer and healthier ...

Read More >

BIO Releases Points to Consider on Truthful and Non-Misleading Product Communication

Publish Date: 8/4/2016, Created By: BIOtechNOW Editor

Today, BIO releases Points to Consider on Truthful and Non-Misleading Product Communication. This document advances the dialogue on this issue toward achieving the shared aim of getting the right medicine to the right patient at the right time. The current “Information Age” holds significant promise to improve the ability of stakeholders to make well-informed healthcare decisions.  Never before has information about healthcare interventions, including innovative medicines, been so readily available from so many different sources and through ...

Read More >

Take Action: Sarcoma Awareness Month

Publish Date: 7/18/2016, Created By: BIOtechNOW Editor

The pages on the calendar have quickly turned and July is again upon us.  For most, July means freedom from school, a summer vacation, or celebrating our nation’s independence.  But those of us in the sarcoma community know that this month means something else as well.  As we know, July is Sarcoma Awareness Month. Why do we have a Sarcoma Awareness Month?  Simply, sarcoma is still considered to be the “forgotten cancer.”  Our efforts to encourage ...

Read More >

Bloomberg Caught Spreading Another Inaccurate “False Alarm” About Drug Prices

Publish Date: 6/29/2016, Created By: Jim Greenwood

I was deeply disturbed by Bloomberg’s inaccurate report this morning that attempted to examine drug costs. The article claims it “decodes [our industry’s]…pricing practices.” But, in reality, it does no such thing. It fails to take in the full picture of biopharmaceutical successes and failures; admits its “proof” is merely guesstimates from an organization that wasn’t involved in pricing decisions; and in some cases, it just plain gets the facts wrong. First, this article myopically ...

Read More >

Stop Demeaning the Healthy Dialogue Between Doctors and Drug Companies

Publish Date: 6/28/2016, Created By: Jim Greenwood

A recent report in The Wall Street Journal entitled, “Even Cheap Meals Influence Doctors’ Drug Prescriptions, Study Suggests,” attempts to suggest an untoward influence resulting from drug company-sponsored physician education events. After reading the full study, it is clear that the WSJ author not only misinterpreted the conclusions of the study, but completely discounts the role that companies have in educating physicians about their products. Contrary to the author’s point, communication between drug companies and ...

Read More >

PwC Report Finds Medicines Still Small Share of Overall Health Spending

Publish Date: 6/27/2016, Created By: Stacey Matusko

A new report from PwC’s Health Research Institute, Medical Cost Trend: Behind the Numbers 2017, offers evidence that medicines continue to represent a small portion of overall healthcare spending. The report highlighted that half of all medical costs come from hospital spending: 30 percent from hospital inpatient and 19 percent from hospital outpatient. Physicians account for another 30 percent, while prescription drugs account for 17 percent. With this breakdown comes the warning that it is ...

Read More >

Thank you to our 2016 Sponsors

Double Helix Sponsors

Helix Sponsors

Premier Sponsors